Benzinga's Top #PreMarket Gainers

Biodel Inc BIOD shares jumped 42.07% to $2.06 in pre-market trading after the company reported positive preliminary results from Phase 2a clinical trial of BIOD-531. BIND Therapeutics, Inc.BIND shares rose 40.78% to $7.25 in pre-market trading after the company provided clinical update for BIND-014. NephroGenex, Inc. NRX shares jumped 14.55% to $10.55 in pre-market trading after the company received positive advice from the European Medicines Agency Regarding its Phase 3 program with Pyridorin. Neurocrine Biosciences Inc. NBIX shares surged 13.30% to $24.79 in pre-market trading after AbbVie Inc. ABBV, in cooperation with Neurocrine Biosciences, announces positive top-line results from Phase 3 study of investigational medicine elagolix. Amicus Therapeutics, Inc.FOLD shares gained 11.24% to $9.50 in the pre-market trading session following the report of additional positive data on important cardiac endpoint.